• lifeIMAGE

  Participated · Equity · May 2015

  lifeIMAGE operates a medical-grade image exchange network that combines local network image sharing with a secure cloud to make patients' imaging records accessible across health systems and care teams. The platform is deployed at hundreds of leading healthcare organizations and supports large implementations at academic medical centers, trauma centers, oncology centers and pediatric facilities. The network has been adopted by more than 120 multi-site health systems, nearly 450 hospitals using the platform across their campuses, plus another 700 hospitals joined for image exchange—exceeding 1,100 hospitals in total. The company reports about 90,000 clinical users across all 50 U.S. states and more than 90 countries, and that providers have shared more than two billion medical images through the network. lifeIMAGE says it is continuing to build out and enhance its intelligent, interoperable health data network and to expand strategic partnerships with industry leaders. lifeIMAGE provides a medical image exchange platform deployed at hundreds of healthcare organizations to facilitate the e-sharing of medical imaging information among hospitals, radiology groups, physicians and patients. The network consists of more than 120 multi-site health systems that include academic medical centers, pediatric facilities, certified trauma centers, oncology centers of excellence and imaging providers. Led by CEO and co-founder Hamid Tabatabaie, the company connects a broad set of care providers and imaging organizations. lifeIMAGE closed a $17.5M round of financing to support its operations. The company intends to use the funds to expand resources for its customer base, increase network capabilities and implement go-to-market initiatives. The business is based in Newton, Massachusetts. lifeIMAGE provides hospitals with tools to facilitate the secure electronic exchange of x-ray, CT, MRI, nuclear medicine, echocardiography, ultrasound and other diagnostic imaging exams in and out of their health care enterprise. Led by CEO Hamid Tabatabaie and based in Newton, MA, the company operates a network for sharing medical images and related health information. Its service has been used by more than 29,000 people in 68 countries to share over 410 million medical images. The company closed a $15M Series C round of financing and intends to use the capital to expand operations. The core product focuses on interoperability and secure image exchange for health care providers. Life Image offers cloud-based software that facilitates transferring, indexing and searching of digital medical images, starting with radiology (MRI, X-ray) and expanding to a variety of products and services for physicians, providers, and patients. The company provides open application programming interfaces to help healthcare IT vendors exchange imaging data and a service to attach medical images to electronic health records. In June it launched a publishing engine for its OutBox cloud service, used by major health systems to securely and automatically share imaging results. LifeIMAGE Networks tracks usage to review trends and identify opportunities for improvement or expansion. The company positions its products as addressing $10–$20 billion in inefficiencies from manual image transfer and sits within a medical informatics market Frost & Sullivan estimates at about $6.5 billion. Life Image counts workflows and security improvements as core differentiators versus CD/DVD-based image exchange. Life Image operates a cloud-based platform that enables secure, easy-to-deploy exchange of diagnostic images and medical information among physicians, hospitals and patients. The platform supports use cases such as replacing CD intake workflows, enabling radiology departments to send information to referring physicians, and allowing patients to send imaging to out-of-state specialists. lifeIMAGE says its network has been adopted by over 50 leading medical centers in the United States and touts recognition from The Wall Street Journal’s 2010 Technology Innovation Awards. The company emphasizes that timely access to medical information improves decision-making, saves lives and reduces costs. Life Image’s technology is positioned as a collaborative solution for hospitals, radiology departments and patients. The company is based in Newton, MA and recently undertook a new capital raise.

• Quotient Biodiagnostics

  Led · Equity · Feb 2013

  Quotient Biodiagnostics is a transfusion diagnostics group that serves major transfusion diagnostic companies as a product development and supply chain partner and also supplies products directly to the blood banking community. The group is developing a next‑generation automation platform for transfusion diagnostics intended to improve clinical decision‑making and laboratory efficiency. Quotient’s North American sales and marketing business is based in the USA, while Alba Bioscience is its product development and manufacturing arm. The company is pursuing plans to build a new facility to expand its liquid reagent business in Scotland. Management has appointed Ed Farrell (formerly of Siemens Healthcare Diagnostics) as corporate President to lead the automation platform project toward commercial launch. Operationally the company reports key business areas with revenue growth exceeding 50% versus the prior year and has raised significant new equity to fund development and expansion. Quotient Biodiagnostics is a transfusion diagnostics group that supplies trusted transfusion diagnostics products to the US blood banking community. Its products are manufactured by Alba Bioscience, the group's Scotland-based product development and manufacturing arm. Quotient Biodiagnostics, Inc. is the group's North American sales and marketing business. Led by Executive Chairman and Founding Shareholder Paul Cowan, the company is developing an automated transfusion diagnostics platform. The company intends to use new capital to expand US commercial operations and to grow manufacturing and product development operations in Edinburgh, Scotland. It recently completed an $11.2M growth equity financing to support these plans.

• Tactile Medical

  Participated · Series B · Oct 2012

  Tactile Systems Technology is a medical device company headquartered in Minneapolis focused on at-home treatment of edema and vascular disease. Its core product, the Flexitouch® system, is a programmable pneumatic compression device with U.S. FDA 510(k) clearance for lymphedema and chronic wounds. The company serves tens of thousands of patients across the U.S. and addresses a condition that affects more than one million people annually in the U.S. The recent financing is intended to fund acquisition of a leading new product and intellectual property rights for additional lymphedema technology; the acquired technology already has 510(k) clearance and an assigned Medicare reimbursement code. Tactile says the new technologies will allow it to update solutions, strengthen its core business, fill gaps in current markets and expand into at-home treatments for other vascular diseases and chronic wound care. Management plans to use the proceeds to augment the existing product line, including the Flexitouch system, and advance the standard of care for chronic diseases at home.

• Quotient

  Led · Equity · Mar 2012

  Quotient Biodiagnostics develops and supplies transfusion diagnostic products and provides product development and manufacturing services to major transfusion diagnostic companies and the blood banking community. The Group highlights a track record of over 30 years ensuring safe and reliable blood transfusions. Alba Bioscience in Scotland serves as the product development and manufacturing arm, while Quotient Biodiagnostics, Inc. handles North American sales and marketing. Quotient plans to use new capital to grow US commercial operations, expand manufacturing and product development in Edinburgh, and accelerate development of a next‑generation automated transfusion diagnostics platform. The company completed an $11.2 million growth equity financing led by Galen Partners. Galen will take board seats and the company added an additional non‑executive director as part of the transaction.

• Sharecare

  Led · Equity · Jan 2012

  Sharecare offers a suite of digital health and population-health products and has expanded its AI capabilities through acquisitions, notably Healthways' population health business and Doc.AI. The company licenses tools such as Doc.AI's Covid-19 evaluation tool and a mental-health chatbot to health plans, and works with plans on claims analytics and predicting medical events. CEO Jeff Arnold has described the company's aim as building a "Facebook for health" to drive vaccinations, mental-health support, care navigation and next-best-action guidance. Financially, reported revenue declined from $342 million in 2018 to $328 million in 2020, with a net loss of $61 million in 2020 (vs. $39M in 2019 and $55M in 2018). Sharecare projects revenue of $396 million in 2021 and $512 million in 2022, and says sales have picked up since the pandemic slowdown, adding clients such as Delta Air Lines. The company is pursuing a public listing via a SPAC merger while continuing to deepen strategic partnerships with payers like Anthem. Sharecare operates a comprehensive digital engagement and virtual care platform that delivers personalized health content, clinically validated tools, and provider solutions to individuals, employers, health plans, and providers. The platform includes data management tools and artificial intelligence capabilities to identify and close gaps in care and to enable providers to prescribe digital therapeutics and clinical programs through a secure, unified interface. Sharecare plans to co-develop consumer-facing offerings with health system partners and to integrate with electronic medical records to personalize care and improve outcomes. In Summer 2021 Sharecare’s virtual care platform was slated to roll out to Wellstar’s 24,000 team members. To support these strategic partnerships and custom development, Wellstar made a $10 million strategic investment in Sharecare. Sharecare also announced a definitive merger agreement with Falcon Capital Acquisition Corp. on February 12, 2021. Sharecare operates a comprehensive mobile health platform that provides personalized health profiles, evidence‑based programs, coaching tools and connections to health professionals and services. The platform serves individuals and also enables providers, employers and health plans to scale outcomes‑based health and wellness solutions across populations. Sharecare emphasizes data‑driven, frictionless technologies and clinically validated protocols to move users from assessment to action. The company highlights plans to expand its impact on individual and community well‑being, including initiatives focused on Georgia. Sharecare is based in Atlanta and Columbus, Georgia, and says partnerships like the one with Aflac will help accelerate its mission. Financially, the company reports it has raised more than $425 million in total capital since founding. Sharecare is an AI-powered digital health platform that leverages smartphones to give users access to personalized care and health management in a single place. Founded in 2010 and based in Atlanta, GA, the company applies artificial intelligence to aggregated behavioral data in real time to personalize recommendations and predict and influence positive outcomes. Its platform targets employees, health plan members, patients, caregivers and self-motivated individuals, driving daily engagement through a holistic focus on health. Sharecare aggregates a critical mass of behavioral data to deliver tailored recommendations and simplify health management for individuals. The company is led by president Justin Ferrero and was founded by Jeff Arnold and Dr. Mehmet Oz. The article does not disclose revenues or user metrics. Sharecare provides a comprehensive digital health platform that integrates personalization, interoperability and daily engagement to connect people with the healthcare system. The company has focused on population health solutions for large employers and health plans in addition to its provider and consumer offerings. Sharecare has integrated capabilities through building and acquisitions, including its 2016 acquisition of Healthways, and offers programs such as Dr. Ornish’s Program for Reversing Heart Disease. HMSA is rolling out Sharecare’s platform statewide in Hawaii, with ambassadors and employees already onboarded and deployment to all residents expected this summer. Sharecare plans to make the platform available to other health plans and employers and to add additional content, including the Blue Zones Project and Dr. Ornish program later this year. The company has said it is developing immersive health experiences that integrate virtual reality and 360-degree video to improve health engagement.

No current team members are available.